Humulin S (Soluble)

Humulin S (Soluble) is a recombinant human insulin injection solution containing insulin human (rDNA) at the standard concentration for subcutaneous, intramuscular, or intravenous administration. It is a prescription‑only product marketed in the European Union and belongs to the insulin class of antidiabetic agents. The formulation is supplied as a clear, sterile solution for use in the management of diabetes mellitus in adult and pediatric patients.

Humulin S is indicated for the treatment of hyperglycemia in patients with diabetes mellitus.

- Type 1 diabetes mellitus as basal insulin replacement - Type 2 diabetes mellitus when oral agents are insufficient - Adjunct to diet and exercise for glycemic control - Intravenous infusion in hospital settings for rapid glucose lowering - Use in pediatric patients with type 1 diabetes - Use as part of a basal‑bolus insulin regimen

Adverse reactions to Humulin S may vary in frequency and severity.

Common: - Hypoglycemia (low blood glucose) - Pain, redness, or swelling at the injection site - Lipodystrophy (localized fat accumulation or loss) - Weight gain - Mild allergic skin reactions such as rash or itching

Serious: - Severe hypoglycemia with neuroglycopenic symptoms - Anaphylactic or severe systemic allergic reaction - Edema or fluid retention leading to heart failure

When prescribing Humulin S, clinicians should consider several safety factors.

- Regular monitoring of blood glucose to adjust dose as needed - Caution in patients with hypoglycemia unawareness or frequent episodes - Dose adjustments may be required during acute illness, surgery, or changes in physical activity - Use carefully in renal or hepatic impairment because insulin clearance may be reduced - Pregnancy and lactation safety data are limited; evaluate risk‑benefit before use - Ensure proper storage (refrigerated, protect from light) and discard after the indicated in‑use period

Humulin S can interact with other medicines, affecting glucose control or insulin action.

Avoid: - Non‑selective beta‑blockers, which may mask hypoglycemia symptoms - Monoamine oxidase (MAO) inhibitors, which can potentiate insulin’s glucose‑lowering effect - Thiazide diuretics, which may increase blood glucose levels

Use with caution: - Systemic glucocorticoids, which raise blood glucose and may require higher insulin doses - Recombinant human growth hormone, which can reduce insulin sensitivity - ACE inhibitors or angiotensin‑II receptor blockers, which may enhance insulin sensitivity and increase risk of hypoglycemia - Alcohol consumption, especially in excess, which can cause delayed hypoglycemia